Insider · CIK 0001499075
Jeffrey Tate
Files at CYTH (Cyclo Therapeutics, Inc.). First filing Apr 24, 2023, latest Apr 24, 2023.
In brief
Jeffrey Tate files SEC Form 4 as COO and director at CYTH (Cyclo Therapeutics, Inc.). Since Apr 24, 2023, Jeffrey Tate has reported 1 open-market buy worth $21k and 0 open-market sells worth $0, the latest filed on Apr 24, 2023.
A track record needs three past buys with six months of prices behind them; Jeffrey Tate has 0, so none is measured yet.
The newest scored trade: bought $21k of CYTH on Apr 20, 2023, filed Apr 24, 2023, scored 45 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Cyclo Therapeutics, Inc. | $21k 29,941 shares | +93% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | CYTH Cyclo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +110,732 | $0.00 | $0 | 110,732 | Jun 5, 2024 |
| Oct 20, 2023 | CYTH Cyclo Therapeutics, Inc. | XIn-the-money exercise Common Stock | +29,941 | $0.71 | $21k | 92,042 | Oct 23, 2023 |
| Oct 20, 2023 | CYTH Cyclo Therapeutics, Inc. | XIn-the-money exercise Warrant to Purchase Common Stockderivative | -29,941 | $0.13 | $3,743 | 0 | Oct 23, 2023 |
| Oct 20, 2023 | CYTH Cyclo Therapeutics, Inc. | POpen-market purchase Warrant to Purchase Common Stockderivative | +32,935 | - | - | 32,935 | Oct 23, 2023 |
| Apr 20, 2023 | CYTH Cyclo Therapeutics, Inc. | POpen-market purchase Common Stock | +29,941 | $0.71 | $21k | 62,101 | Apr 24, 2023 |
| Apr 20, 2023 | CYTH Cyclo Therapeutics, Inc. | POpen-market purchase Warrant to Purchase Common Stockderivative | +29,941 | $0.13 | $3,743 | 29,941 | Apr 24, 2023 |
| Mar 7, 2023 | CYTH Cyclo Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +41,036 | $0.00 | $0 | 41,036 | Mar 9, 2023 |
Questions about Jeffrey Tate
Answered from the filings on this page, as of the latest one.
Is Jeffrey Tate buying or selling?
Not in the last 12 months. Jeffrey Tate's latest open-market trade on SEC Form 4 was bought $21k of CYTH on Apr 20, 2023.
How did Jeffrey Tate's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Tate has 0.
Where does Jeffrey Tate file Form 4?
Jeffrey Tate has filed Form 4 at CYTH (Cyclo Therapeutics, Inc.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.